Market Cap 60.63M
Revenue (ttm) 0.00
Net Income (ttm) -28.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 803,232
Avg Vol 969,934
Day's Range N/A - N/A
Shares Out 34.65M
Stochastic %K 63%
Beta 1.19
Analysts Strong Sell
Price Target $10.75

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 875 3192
Address:
101 Lindenwood Drive, Suite 225, Malvern, United States
BioRich
BioRich Aug. 4 at 8:16 PM
$XBI Today's Bio Winners: 1) $EWTX 2) $COGT 3) $DRTS 4) $ANVS 5) VVOS (Going wild AH). Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
Dopamineaddict
Dopamineaddict Aug. 4 at 7:28 PM
$ANVS What is the bear theory on dilution here? Annovis does not utilize any of the OLE data to excite the market? They are performing skin-biopsies for alpha-synuclein and collecting myriad other biomarkers to hide it in their data-room? Despite currently treating a large group with Parkinson’s dementia that is relevant to their current AD trial, they will just sit on the data? That their patients are tracking tremors/movement on Apple Watches for the sake of curiosity? Come now, this is a coiled spring! They are simply timing their shots.
2 · Reply
ScottHopko
ScottHopko Aug. 4 at 5:35 PM
$ANVS nice pop!
0 · Reply
junkjar291
junkjar291 Aug. 4 at 4:42 PM
$ANVS After 2Q 10Q , they will raise, same as what she did in May. If stock holds here then around $1.5 or below , if it craters after seeing numbers in 10q, then get ready for below $1.0
1 · Reply
ppl_first
ppl_first Aug. 4 at 4:40 PM
$ANVS married to this bitch until it goes back to $5
0 · Reply
Dopamineaddict
Dopamineaddict Aug. 4 at 4:30 PM
$ANVS Again, if they have compelling OLE data, they could gain enough momentum to secure funding through warrants, and small ATM raises. This very speculative, but it would be a viable strategy.
0 · Reply
moneyonthebrain
moneyonthebrain Aug. 4 at 3:40 PM
$ANVS I don't really agree with junkjar, but I do have some concerns: Maria announced she had enough money to get to 6-month results, raised an additional $15 million, and now only has $19 million with two quarters to go? In the past, Maria has said she wants to pay up front for clinical trial expenses since it can be cheaper that way, and the expensive enrollment of the phase 3 trial is over, so ANVS's cash burn might be dropping dramatically and they really might have plenty of cash to get to 6-month results, but I hope all that is explicitly explained in the upcoming earnings report so the threat of dilution is alleviated...
2 · Reply
junkjar291
junkjar291 Aug. 4 at 2:19 PM
$ANVS Maria warrant math is not working, instead her warrants are acting as ceiling for stock. Last raise warrants are at $2.25 and vested immediately, no locking period. $2.25 warrants have 6month locking, so that puts close to Nov and then there is $5 warrants from last year. Maybe they thought announcing AD full enrollment will boost the stock and at least $2.25 and $2.5 warrants will be in money and some investor will cash out to get out of this POS for good, but stock never reached $2.25, now Maria stuck with no money and need to raise at penny.
0 · Reply
junkjar291
junkjar291 Aug. 4 at 1:05 PM
$ANVS No cash, another massive raise is coming this month. As of march quater cash was 14mil, then they did two raise of 10mil and 15 mil . But as of june quarter they had 19 mil, which mean last quarter they spent 19 mil. Even if one consider expense will be low going forward, 19 mil is not enough for 6month readout.
1 · Reply
Madsj79
Madsj79 Aug. 4 at 9:08 AM
$ANVS Updated Investor presentation
1 · Reply
Latest News on ANVS
Annovis Bio Slides: Investor presentation

Aug 3, 2026, 9:00 AM EDT - 1 day ago

Annovis Bio Slides: Investor presentation


Annovis Bio initiated with a Buy at Roth Capital

2026-07-07T20:16:13.000Z - 4 weeks ago

Annovis Bio initiated with a Buy at Roth Capital


Annovis Bio announces full enrollment for buntanetap trial

2026-07-07T11:20:30.000Z - 4 weeks ago

Annovis Bio announces full enrollment for buntanetap trial


Annovis Bio promotes Cheng Fang to chief scientific officer

2026-07-01T12:05:20.000Z - 4 weeks ago

Annovis Bio promotes Cheng Fang to chief scientific officer


Annovis Bio regains NYSE listing compliance

2026-05-26T15:07:38.000Z - 2 months ago

Annovis Bio regains NYSE listing compliance


Annovis Bio Regains NYSE Listing Compliance

May 26, 2026, 8:00 AM EDT - 2 months ago

Annovis Bio Regains NYSE Listing Compliance


Annovis Bio 7.9M share Spot Secondary priced at $1.90

2026-05-20T12:20:11.000Z - 2 months ago

Annovis Bio 7.9M share Spot Secondary priced at $1.90


Annovis Bio Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

Annovis Bio Quarterly report: Q1 2026


Annovis Bio Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

Annovis Bio Earnings release: Q1 2026


Annovis Bio Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 2 months ago

Annovis Bio Slides: Corporate presentation


Annovis Bio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Annovis Bio Proxy statement: Proxy filing


Annovis Bio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Annovis Bio Proxy statement: Proxy filing


Annovis Bio Slides: Corporate presentation

Apr 8, 2026, 7:00 AM EDT - 4 months ago

Annovis Bio Slides: Corporate presentation


Annovis Bio secures U.S. patent for buntanetap

2026-04-02T11:54:03.000Z - 4 months ago

Annovis Bio secures U.S. patent for buntanetap


Annovis Bio Slides: Corporate presentation

Mar 24, 2026, 7:00 AM EDT - 4 months ago

Annovis Bio Slides: Corporate presentation


Annovis Bio enters partnership with NeuroRPM

2026-03-19T11:56:46.000Z - 4 months ago

Annovis Bio enters partnership with NeuroRPM


Annovis Bio sees cash runway to 3Q26

2026-03-16T11:41:50.000Z - 5 months ago

Annovis Bio sees cash runway to 3Q26


Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year

2026-03-16T11:35:20.000Z - 5 months ago

Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year


Annovis Bio Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Annovis Bio Earnings release: Q4 2025


Annovis Bio Annual report: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Annovis Bio Annual report: Q4 2025


Annovis to Host Corporate Update Webinar on January 28, 2026

Dec 16, 2025, 8:00 AM EST - 8 months ago

Annovis to Host Corporate Update Webinar on January 28, 2026


Annovis Announces Two Presentations at the CTAD 2025 Conference

Nov 24, 2025, 8:00 AM EST - 9 months ago

Annovis Announces Two Presentations at the CTAD 2025 Conference


Annovis announces FDA meeting to discuss PDD program

2025-11-18T14:39:45.000Z - 9 months ago

Annovis announces FDA meeting to discuss PDD program


Annovis Bio reports Q3 EPS (37c) vs. (97c) last year

2025-11-12T13:11:18.000Z - 9 months ago

Annovis Bio reports Q3 EPS (37c) vs. (97c) last year


Annovis Bio sees cash runway to 3Q26

2025-11-12T13:10:52.000Z - 9 months ago

Annovis Bio sees cash runway to 3Q26


Annovis Bio Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 9 months ago

Annovis Bio Earnings release: Q3 2025


Annovis Bio Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 9 months ago

Annovis Bio Quarterly report: Q3 2025


Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 25, 2025, 7:30 AM EDT - 11 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer


Annovis Bio Quarterly report: Q2 2025

Aug 12, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Quarterly report: Q2 2025


Annovis Bio Earnings release: Q2 2025

Aug 12, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q2 2025


Annovis Completes Full Patent Transfer to Crystal Buntanetap

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap


Annovis Bio Transcript: Status Update

Jun 24, 2025, 4:30 PM EDT - 1 year ago

Annovis Bio Transcript: Status Update


Annovis to Host Webinar and Live Q&A on June 24, 2025

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Annovis to Host Webinar and Live Q&A on June 24, 2025


Annovis Bio Earnings release: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q1 2025


Annovis Bio Quarterly report: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Quarterly report: Q1 2025


Annovis Bio Proxy statement: Proxy Filing

May 1, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Proxy statement: Proxy Filing


Annovis Bio Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Proxy statement: Proxy Filing


Annovis Bio Appoints Hui Liu as Director of Biostatistics

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics


Annovis Bio Annual report: Q4 2024

Mar 21, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Annual report: Q4 2024


Annovis Bio Earnings release: Q4 2024

Mar 21, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q4 2024


Annovis to Host Patients' Live Forum on February 27, 2025

Feb 19, 2025, 8:30 AM EST - 1 year ago

Annovis to Host Patients' Live Forum on February 27, 2025


Annovis Bio, Inc. Announces Proposed Public Offering

Jan 31, 2025, 8:14 PM EST - 1 year ago

Annovis Bio, Inc. Announces Proposed Public Offering


BioRich
BioRich Aug. 4 at 8:16 PM
$XBI Today's Bio Winners: 1) $EWTX 2) $COGT 3) $DRTS 4) $ANVS 5) VVOS (Going wild AH). Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
Dopamineaddict
Dopamineaddict Aug. 4 at 7:28 PM
$ANVS What is the bear theory on dilution here? Annovis does not utilize any of the OLE data to excite the market? They are performing skin-biopsies for alpha-synuclein and collecting myriad other biomarkers to hide it in their data-room? Despite currently treating a large group with Parkinson’s dementia that is relevant to their current AD trial, they will just sit on the data? That their patients are tracking tremors/movement on Apple Watches for the sake of curiosity? Come now, this is a coiled spring! They are simply timing their shots.
2 · Reply
ScottHopko
ScottHopko Aug. 4 at 5:35 PM
$ANVS nice pop!
0 · Reply
junkjar291
junkjar291 Aug. 4 at 4:42 PM
$ANVS After 2Q 10Q , they will raise, same as what she did in May. If stock holds here then around $1.5 or below , if it craters after seeing numbers in 10q, then get ready for below $1.0
1 · Reply
ppl_first
ppl_first Aug. 4 at 4:40 PM
$ANVS married to this bitch until it goes back to $5
0 · Reply
Dopamineaddict
Dopamineaddict Aug. 4 at 4:30 PM
$ANVS Again, if they have compelling OLE data, they could gain enough momentum to secure funding through warrants, and small ATM raises. This very speculative, but it would be a viable strategy.
0 · Reply
moneyonthebrain
moneyonthebrain Aug. 4 at 3:40 PM
$ANVS I don't really agree with junkjar, but I do have some concerns: Maria announced she had enough money to get to 6-month results, raised an additional $15 million, and now only has $19 million with two quarters to go? In the past, Maria has said she wants to pay up front for clinical trial expenses since it can be cheaper that way, and the expensive enrollment of the phase 3 trial is over, so ANVS's cash burn might be dropping dramatically and they really might have plenty of cash to get to 6-month results, but I hope all that is explicitly explained in the upcoming earnings report so the threat of dilution is alleviated...
2 · Reply
junkjar291
junkjar291 Aug. 4 at 2:19 PM
$ANVS Maria warrant math is not working, instead her warrants are acting as ceiling for stock. Last raise warrants are at $2.25 and vested immediately, no locking period. $2.25 warrants have 6month locking, so that puts close to Nov and then there is $5 warrants from last year. Maybe they thought announcing AD full enrollment will boost the stock and at least $2.25 and $2.5 warrants will be in money and some investor will cash out to get out of this POS for good, but stock never reached $2.25, now Maria stuck with no money and need to raise at penny.
0 · Reply
junkjar291
junkjar291 Aug. 4 at 1:05 PM
$ANVS No cash, another massive raise is coming this month. As of march quater cash was 14mil, then they did two raise of 10mil and 15 mil . But as of june quarter they had 19 mil, which mean last quarter they spent 19 mil. Even if one consider expense will be low going forward, 19 mil is not enough for 6month readout.
1 · Reply
Madsj79
Madsj79 Aug. 4 at 9:08 AM
$ANVS Updated Investor presentation
1 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 3 at 8:00 PM
$ANVS Drop it
0 · Reply
Absynth92
Absynth92 Aug. 3 at 3:52 PM
$ANVS if phase 3 is successful, easy 10-20x. Then, commercialization might take a year or two, if that is successful, we'll probably see 100x from today's price (assuming no more dilution).
1 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 3 at 12:58 PM
$ANVS Data chasers will come ****Target price $132.00 per share ****
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 3 at 12:56 PM
$ANVS Data pay out ranges Phase 1 - paid out like $24---> $97 or something Phase 2- paid out like $12 ---> to $18 or something Phase 3- is at well might as well be ALL TIME lows for a phase 3 Alzheimers play
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 3 at 12:50 PM
$ANVS Well how much is Phase 3 Alzheimers data worth... 10 to 14 Billion market cap Anvs trades below 100 million market cap
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 3 at 12:48 PM
$ANVS If Data was weird why are institutions adding. Know more August 14th
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 3 at 12:48 PM
$ANVS Highest short % going into 6 month data. Short Squeeze will be fun
0 · Reply
NolAsrtormZ
NolAsrtormZ Aug. 3 at 12:47 PM
$ANVS New watchers ** i see Well, Re-cap Data gambler entered
0 · Reply
Veni_Vidi_Vici
Veni_Vidi_Vici Aug. 3 at 12:42 PM
$ANVS I am no expert. Do your own due diligence. Understand the risks before investing in a clinical stage biotech. Annovis Followers on Stocktwits = 10,261
2 · Reply
FRF
FRF Aug. 2 at 12:13 PM
1 · Reply
FRF
FRF Aug. 2 at 12:10 PM
0 · Reply
clearvision
clearvision Aug. 2 at 5:19 AM
$ANVS I am feeling better and thinking better after a few months on buntanetap. This drug should have been approved ten years ago.
3 · Reply